Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MEDLEYTSE:4480 +0.48%67 EBIT per Share is 円79.07 as of Dec. 2025. GuruFocus rates TSE:4480 with a GF Score™ of 67/100 and a GF Value™ of 円6,814.85 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 526 Healthcare Providers & Services companies, MEDLEY ranks better than 61.03% on this metric.
MEDLEY's EBIT per Share for the
three
months ended in Dec. 2025 was 円17.53.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was 円79.07.
During the past 12 months, the average EBIT per Share Growth Rate of MEDLEY was -5.60% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 19.30% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 43.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for MEDLEY's EBIT per Share or its related term are showing as below:
TSE:4480'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 19.3 Med: 66.8 Max: 87.7
Current: 19.3
During the past 7 years, the highest 3-Year average EBIT per Share Growth Rate of MEDLEY was 87.70% per year. The lowest was 19.30% per year. And the median was 66.80% per year.
TSE:4480's 3-Year EBIT Growth Rate is ranked better than 61.03% of 526
companies
in the Healthcare Providers & Services industry
Industry Median: 11.95
vs TSE:4480: 19.30
MEDLEY's EBIT for the
three
months ended in Dec. 2025 was 円561 Mil.
MEDLEY (TSE:4480) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
MEDLEY EBIT per Share Related Terms
MEDLEY EBIT per Share Historical Data
* Premium members only.
The historical data trend for MEDLEY's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円79.07
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEDLEY (TSE:4480) has a EBIT per Share of 円79.07 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on MEDLEY and its competitors. According to the industry distribution chart, MEDLEY ranks #205 out of 526 companies in the Healthcare Providers & Services industry, placing it in the top 39%.
Is MEDLEY's EBIT per Share too high?
MEDLEY's current EBIT per Share is 円79.07. Based on the distribution chart, MEDLEY ranks #205 out of 526 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, MEDLEY has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does MEDLEY's EBIT per Share compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, MEDLEY ranks #205 out of 526 companies for EBIT per Share. This puts MEDLEY in the upper half of its industry. The industry median EBIT per Share is 11.95. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Healthcare Providers & Services company?
The median EBIT per Share among Healthcare Providers & Services companies is 11.95, based on 526 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on MEDLEY and its competitors. For the Healthcare Providers & Services industry, the median EBIT per Share is 11.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MEDLEY's current EBIT per Share is 円79.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MEDLEY stock overvalued right now?
Based on GuruFocus' analysis, MEDLEY (TSE:4480) is currently considered Significantly Undervalued. The stock's GF Value™ is 円6,814.85, compared to a current price of 円2,112.00 — trading 69% below its estimated fair value. The current EBIT per Share is 円79.07. MEDLEY's overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For MEDLEY (TSE:4480), the current EBIT per Share is 円79.07 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MEDLEY (TSE:4480) Overvalued in 2026?
Based on GuruFocus' analysis, MEDLEY stock appears to be undervalued.
The current stock price of 円2,112.00 is trading 69% below its estimated GF Value™ of 円6,814.85.
GuruFocus considers MEDLEY to be Significantly Undervalued.
Key valuation signals for TSE:4480:
EBIT per Share: 円79.07
GF Value™: 円6,814.85 vs. price of 円2,112.00 (69% below fair value)
No single metric tells the full story. See the TSE:4480 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MEDLEY Inc is engaged in providing medical information service for patients, and nursing care, a nursing care information service for citizens resolving issues in the field of medical healthcare. It provides its services through two platforms, Recruitment Platform Business which provides human resource recruitment systems in the medical and healthcare field and related businesses; and Medical Platform Business that is a telemedicine system for both patients and medical institutions.
67GF Score
Get the complete analysis for TSE:4480
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4480 has been successfully added to your 
